Efficacy, safety, Low density lipoprotein cholesterol lowering, and calculated 10-year cardiovascular risk reduction of alirocumab and evolocumab in addition to maximal tolerated cholesterol lowering therapy: a post-commercialization study-Reference-Cited by-同舟云学术

Efficacy, safety, Low density lipoprotein cholesterol lowering, and calculated 10-year cardiovascular risk reduction of alirocumab and evolocumab in addition to maximal tolerated cholesterol lowering therapy: a post-commercialization study

Published:2017-01-23 Issue:1 Volume:16 Page:
ISSN:1476-511X
Container-title:Lipids in Health and Disease
language:en
Short-container-title:Lipids Health Dis

Author:

Shah Parth,Glueck Charles J.,Goldenberg Naila,Min Sarah,Mahida Chris,Schlam Ilana,Rothschild Matan,Huda Ali,Wang Ping

Funder

Jewish Hospital Lipoprotein Research Fund

Publisher

Springer Science and Business Media LLC

Subject

Biochemistry, medical,Clinical Biochemistry,Endocrinology,Endocrinology, Diabetes and Metabolism

Link

http://link.springer.com/content/pdf/10.1186/s12944-017-0416-7.pdf

Reference46 articles.

1. Keenan NL, Shaw KM. Coronary heart disease and stroke deaths - United States, 2006. MMWR Suppl. 2011;60(1):62–6.

2. Mercado CDA, et al. Prevalence of cholesterol treatment eligibility and medication use among adults - united states, 2005–2012. MMWR Morb Mortal Wkly Rep. 2015;64(47):1305–11.

3. Kereiakes DJ, Robinson JG, Cannon CP, Lorenzato C, Pordy R, Chaudhari U, Colhoun HM. Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: the ODYSSEY COMBO I study. Am Heart J. 2015;169(6):906–915 e913.

4. Marks D, Thorogood M, Neil HA, Humphries SE. A review on the diagnosis, natural history, and treatment of familial hypercholesterolaemia. Atherosclerosis. 2003;168(1):1–14.

5. Austin MA, Hutter CM, Zimmern RL, Humphries SE. Genetic causes of monogenic heterozygous familial hypercholesterolemia: a HuGE prevalence review. Am J Epidemiol. 2004;160(5):407–20.

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effectiveness, Safety, and Adherence to Treatment of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors in Real Practice;Clinical Therapeutics;2021-04

2. Insights on the efficacy and safety of PCSK-9 inhibitor in Taiwanese patients;Journal of the Chinese Medical Association;2019-11

3. Safety and tolerability of injectable lipid-lowering drugs: an update of clinical data;Expert Opinion on Drug Safety;2019-05-29

4. Evolving targets for the treatment of atherosclerosis;Pharmacology & Therapeutics;2018-07

5. Economic Evaluation of the PCSK9 Inhibitors in Prevention of the Cardiovascular Diseases;Current Cardiology Reports;2018-05-19